Muzolimine
Chemical compound
- C03CD01 (WHO)
- Withdrawn
- 5-amino-2-[1-(3,4-dichlorophenyl)ethyl]-4H-pyrazol-3-one
- 55294-15-0
N
- 41386
- 37766 N
- 07Z36289ZX
- D05093
Y
- DTXSID50866476
- Interactive image
- O=C1CC(N)=NN1C(C)c2cc(Cl)c(Cl)cc2
InChI
- InChI=1S/C11H11Cl2N3O/c1-6(16-11(17)5-10(14)15-16)7-2-3-8(12)9(13)4-7/h2-4,6H,5H2,1H3,(H2,14,15)N
- Key:RLWRMIYXDPXIEX-UHFFFAOYSA-NN
N
Y (what is this?) (verify)Muzolimine is a high-ceiling loop diuretic.[1] It is a pyrazole diuretic which was used for treatment of hypertension but was withdrawn worldwide because of severe neurological side effects.[2]
Synthesis
Rxn of (1-(3,4-dichlorophenyl)ethyl)hydrazine (1) with ethyl 3-amino-3-ethoxyacrylate (2) leads to a ring-forming two-site reaction and formation of the pyrazoline diuretic agent, muzolimine (3).
References
- ^ Wangemann P, Braitsch R, Greger R (December 1987). "The diuretic effect of muzolimine". Pflügers Archiv. 410 (6): 674–6. doi:10.1007/BF00581331. PMID 3449804. S2CID 19367481.
- ^ Reyes AJ, Leary WP (January 1993). "Clinicopharmacological reappraisal of the potency of diuretics". Cardiovascular Drugs and Therapy. 7 Suppl 1: 23–8. doi:10.1007/BF00877955. PMID 8435374. S2CID 29589710.
- ^ DE 2319278, Möller, Eike; Meng, Karl & Wehinger, Egbert et al., "Diuretisches und antihypertensives Mitel [Diuretic and antihypertensive agent]", published 1974-11-07, assigned to Bayer AG
- ^ E. Möller et al., U.S. patent 3,957,814 (1976 to Bayer); eidem, Experientia 33, 382 (1977).
- v
- t
- e
Diuretics (C03)
(and etacrynic acid)
| CA inhibitors (at PT) | |
|---|---|
| Loop (Na-K-Cl at AL) | |
| Thiazides (Na-Cl at DCT, Calcium-sparing) | |
| Thiazide-likes (primarily DCT) |
| ESC blockers | |
|---|---|
| Aldosterone antagonists |
(DCT and CD)
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
 | This drug article relating to the cardiovascular system is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
